ライフサイエンスコーパス: systolic hypertension

1 atients aged 60 years or older with isolated systolic hypertension.

2 e-associated vascular stiffness and isolated systolic hypertension.

3 olic BP in postmenopausal women with stage 1 systolic hypertension.

4 lay an active role in the pathophysiology of systolic hypertension.

5 adults (aged 60 years or more) with isolated systolic hypertension.

6 y function among older persons with isolated systolic hypertension.

7 patrilat 80 mg daily (n=80) in patients with systolic hypertension.

8 olled trials has been beneficial in isolated systolic hypertension.

9 ch occurs with aging, diabetes, and isolated systolic hypertension.

10 d extend the findings to borderline isolated systolic hypertension.

11 portant in older men and women with isolated systolic hypertension.

12 o 1.87) and 1.68 (1.58 to 1.78) for isolated systolic hypertension, 1.59 (1.43 to 1.76) and 1.45 (1.2

13 four components best describe the data: (1) systolic hypertension, (2) general hypertension, (3) res

14 Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that ini

15 Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, we aimed to in

16 COMbination Therapy in Patients Living With Systolic Hypertension [ACCOMPLISH]; NCT00170950).

17 h age and contributes to the pathogenesis of systolic hypertension and cardiovascular disease in the

18 Treatment of isolated systolic hypertension and combined systolic and diastoli

19 olol for treatment of patients with isolated systolic hypertension and ECG-LVH.

20 TG mice had systolic hypertension and hypertrophy similar to those s

21 ean arterial pressure variably contribute to systolic hypertension and increased cardiovascular risk.

22 (HF-nlEF) is common in aged individuals with systolic hypertension and is frequently ascribed to dias

23 e in aortic stiffness likely further worsens systolic hypertension and its attendant end-organ damage

24 significant and positive association between systolic hypertension and liver expression levels of glu

25 Most importantly, we review the risk of systolic hypertension and pulse pressure hypertension in

26 essure (SBP), the prevalence of uncontrolled systolic hypertension, and cardiovascular mortality attr

27 aortic hypoplasia, calcific atherosclerosis, systolic hypertension, and premature cataract.

28 Hypertension as well as borderline isolated systolic hypertension are associated with elevated risks

29 effective in elderly patients with isolated systolic hypertension, attention has been focused on the

30 ve individuals and individuals with isolated systolic hypertension but not in individuals with diasto

31 Heart failure is often preceded by isolated systolic hypertension, but the effectiveness of antihype

32 the time of scanning are small, but isolated systolic hypertension could cause increases in spurious

33 Better clinical management of systolic hypertension depends on greater insight into th

34 essure that separates patients with isolated systolic hypertension from those with essential hyperten

35 at is characterized by the early presence of systolic hypertension, glomerular hypertension, progress

36 as found in 48 (44%) patients (18 male), and systolic hypertension (>140 mmHg) was found in 69 (63%)

37 Studies of the pathogenesis of systolic hypertension have lagged.

38 ssociation between homocysteine and isolated systolic hypertension in older adults was evaluated usin

39 the United States consist of isolated, mild systolic hypertension in older adults, most of whom have

40 m (SHEP) demonstrated that treating isolated systolic hypertension in older patients decreased incide

41 eine may be related to the cause of isolated systolic hypertension in some individuals.

42 r adults, the authors analyzed data from the Systolic Hypertension in the Elderly Program (1984-1990)

43 The Systolic Hypertension in the Elderly Program (SHEP) demo

44 In the Systolic Hypertension in the Elderly Program (SHEP) tria

45 and women enrolled in the placebo arm of the Systolic Hypertension in the Elderly Program (SHEP).

46 The Systolic Hypertension in the Elderly Program recruited 4

47 The Systolic Hypertension in the Elderly Program recruited 4

48 es confirm the benefits of treating isolated systolic hypertension in the elderly.

49 n contrast to the wealth of data on isolated systolic hypertension involving the systemic circulation

50 Systolic hypertension is common in patients hospitalized

51 Isolated systolic hypertension is the dominant variety.

52 Isolated systolic hypertension is the predominant form of hyperte

53 lic/diastolic hypertension, whereas isolated systolic hypertension (ISH) is common among persons over

54 problem among elderly patients with isolated systolic hypertension (ISH), but the effect of treatment

55 Isolated systolic hypertension (ISH), defined as systolic blood p

56 of stroke in elderly patients with isolated systolic hypertension (ISH).

57 Model-TV demonstrated that mild to moderate systolic hypertension may be relatively well tolerated.

58 edictors of type II outcomes were older age, systolic hypertension on admission, pulmonary disease, a

59 teine remained significantly associated with systolic hypertension (P=.019).

60 efinite hypertension and borderline isolated systolic hypertension predict subsequent cardiovascular

61 ocardial infarction, and borderline isolated systolic hypertension predicts a possible but more modes

62 specially in older patients in whom isolated systolic hypertension predominates, controlling 70% to <

63 METHODS AND COX-1>COX-2 mice developed systolic hypertension relative to wild types (WTs) on a

64 (SBP >or=140 and DBP >or=90 mm Hg), isolated systolic hypertension (SBP >or=140 and DBP <90 mm Hg), i

65 Blood Pressure emphasizes the importance of systolic hypertension (SH), defined as systolic blood pr

66 Patients with isolated systolic hypertension should be treated, but marked dias

67 Low-grade proteinuria and systolic hypertension (SHT) are risk factors for allogra

68 In older persons with isolated systolic hypertension, stepped-care treatment based on l

69 The odds ratios for systolic hypertension suggest a similar but weaker assoc

70 assessed in 128 subjects with uncomplicated systolic hypertension (supine systolic pressure > or =14

71 This review describes the systolic hypertension syndrome as a complex set of hemod

72 up; they were also observed in patients with systolic hypertension (systolic blood pressure > or = 14

73 COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effec

74 te Cox regression modeling demonstrated that systolic hypertension was a significant independent pred

75 Isolated systolic hypertension was associated with increased risk

76 Mild to moderate systolic hypertension was associated with only modest in

77 Borderline isolated systolic hypertension was associated with significantly

78 Elevated PP in systolic hypertension was independent of MAP and was att

79 Hypertension and borderline isolated systolic hypertension were associated with significantly

80 in salt, the EP2-/- mice developed profound systolic hypertension, whereas wild-type mice showed no

81 rosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihyper

82 In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepped-care t

83 ged >/=60 years (older) have mainly isolated systolic hypertension, with major trials attaining systo